163 related articles for article (PubMed ID: 34939129)
21. Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience.
Lukács G; Tóth Z; Sipos D; Csima M; Hadjiev J; Bajzik G; Cselik Z; Semjén D; Repa I; Kovács Á
Ideggyogy Sz; 2018 Mar; 71(3-04):95-103. PubMed ID: 29889468
[TBL] [Abstract][Full Text] [Related]
22. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
23. A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma.
Singh G; Mallick S; Sharma V; Joshi N; Purkait S; Jha P; Sharma MC; Suri V; Julka PK; Mahapatra AK; Singh M; Kale SS; Sarkar C
Neuropathology; 2012 Oct; 32(5):534-42. PubMed ID: 22380407
[TBL] [Abstract][Full Text] [Related]
24. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
25. The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
Brenner A; Friger M; Geffen DB; Kaisman-Elbaz T; Lavrenkov K
Oncology; 2019; 97(5):255-263. PubMed ID: 31288238
[TBL] [Abstract][Full Text] [Related]
26. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
27. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
28. Primary versus secondary gliosarcoma: a systematic review and meta-analysis.
Vuong HG; Dunn IF
J Neurooncol; 2022 Aug; 159(1):195-200. PubMed ID: 35768633
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
30. Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma.
Frandsen S; Broholm H; Larsen VA; Grunnet K; Møller S; Poulsen HS; Michaelsen SR
Front Oncol; 2019; 9():1425. PubMed ID: 31921679
[No Abstract] [Full Text] [Related]
31. Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series.
Castelli J; Feuvret L; Haoming QC; Biau J; Jouglar E; Berger A; Truc G; Gutierrez FL; Morandi X; Le Reste PJ; Thillays F; Loussouarn D; Nouhaud E; Crehange G; Antoni D; Vauleon E; de Crevoisier R; Noel G
J Neurooncol; 2016 Aug; 129(1):85-92. PubMed ID: 27169763
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results.
Galanis E; Buckner JC; Dinapoli RP; Scheithauer BW; Jenkins RB; Wang CH; O'Fallon JR; Farr G
J Neurosurg; 1998 Sep; 89(3):425-30. PubMed ID: 9724117
[TBL] [Abstract][Full Text] [Related]
33. Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
Saito T; Sugiyama K; Hama S; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
Neurosurg Rev; 2018 Apr; 41(2):621-628. PubMed ID: 28887717
[TBL] [Abstract][Full Text] [Related]
34. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
[TBL] [Abstract][Full Text] [Related]
35. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors influencing survival following re-resection for isocitrate dehydrogenase (IDH) -wildtype glioblastoma multiforme - Data from a national neuro-oncology registry.
Hennessy MA; Coyne ZL; O'Halloran PJ; Mullally W; Dablouk M; MacNally S; Morris PG
J Clin Neurosci; 2022 Jan; 95():142-150. PubMed ID: 34929638
[TBL] [Abstract][Full Text] [Related]
37. Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide.
Mallick S; Gandhi AK; Sharma DN; Gupta S; Haresh KP; Rath GK; Julka PK
Childs Nerv Syst; 2015 Dec; 31(12):2341-4. PubMed ID: 26438548
[TBL] [Abstract][Full Text] [Related]
38. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
39. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors in patients with glioblastoma multiforme: focus on the pathologic variants.
Alimohammadi E; Bagheri SR; Sadeghsalehi A; Rizevandi P; Rezaie Z; Abdi A
Acta Neurol Belg; 2020 Dec; 120(6):1341-1350. PubMed ID: 31222512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]